NCT00417807已完成1 期
Open-label Trial of Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors (DSRCT) Expressing PDGF-R
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- Overall tumor response rates
研究概览
简要总结
An open-label, non-comparative study conducted to investigate the activity and safety of imatinib mesylate in refractory desmoplastic small round cell tumors expressing PDGF-R. Patients will be treated up to 12 months, or to disease progression. Tumor will be evaluated according to Recist criteria
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Gleevec/Glivec
Experimental
干预措施: Imatinib mesilate (Drug)
结局指标
主要结局
Overall tumor response rates
时间窗: Assessed every 3 months
An imaging technique (CT scan or MRI) determined tumor response according to RECIST criteria.
次要结局
- Explore how Imatinib cooperated with other treatment modatilities(Survival data was collected until death)
- Safety and tolerability(Safety data collected until patients were no longer in study)
- Conversion rate to surgical resectability(After best tumor response.)
- Mutational analysis of molecular targets of imatinib (at any time during the study)(At any time during the study)
研究者
研究点 (2)
Loading locations...
相似试验
进行中（未招募）
不适用
Open-label trial of imatinib mesylate (Glivec, formerly known as STI571) in combination with vinorelbine (Navelbine) for patients with advanced breast carcinoma - ICOcarcinoma breastMedDRA version: M15Level: LLTClassification code 10007305EUCTR2005-001537-15-DEovartis Pharma GmbH30
终止
2 期
Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)GlioblastomaNCT00171938Novartis30
已完成
3 期
Treatment of Patients With Nephrogenic Systemic Fibrosis With GlivecNephrogenic Systemic FibrosisNCT00981942University of Aarhus10
已完成
1 期
Effect of Imatinib Mesylate and the Pharmacokinetics of Acetaminophen/Paracetamol in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)Chronic Myeloid Leukemia (CML)NCT00428909Novartis Pharmaceuticals12
已完成
2 期
Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionNCT00477269Novartis Pharmaceuticals59